CAS: 5041-67-8; 3-(((2S,3R,4R,5S)-3,4-Dihydroxy-5-(Hydroxymethyl)Tetrahydrofuran-2-yl)Oxy)-5,7-Dihydroxy-2-(4-Hydroxyphenyl)-4H-Chromen-4-One

该化合物是天然化合物,主要见于胡桃树叶和胡桃树的叶和树皮上,特别是朱格兰人,被归类为花草状胶质,这意味着它由与糖分子相连的花生素协会组成.Juglanin展示了各种生物活动,包括抗氧化剂,抗炎剂和潜在的抗微生物特性,这使它对药理研究感兴趣.该化合物以其捕食自由基的能力而著称,这有助于保护其免受氧化性压力的影响.此外,杂草素可能在植物防御机制中发挥作用,帮助保护胡桃树免受虫害和疾病的影响.其溶解性特征各不相同,往往在极地溶剂中更加溶解.对杂醇的研究继续探索其在自然产品化学和草药中的潜在健康利益和应用.

结构式图片

上下游产品

CAS号520-18-3 山奈酚

合成工艺路线路线简述

    📜Kaempherol 3-O-α-L-Arabinofuranoside-7-O-α-L-Rhamnopyranoside置于hesperidinase,Hoac-Naoac Buffer体系中,用 水 作为反应溶剂,化学反应 0.17H,以71 Mg的收率获得产物山柰酚 3-O-Alpha-L-阿拉伯呋喃糖苷
    参考文献:Four Kaempferol Glycosides From Leaves Of Cinnamomum Sieboldii
    标题:Four Kaempferol Glycosides From Leaves Of Cinnamomum Sieboldii
    摘要:
    DOI:10.1016/s0031-9422(00)97707-0

    海关参考信息

    专利信息


    专利号:US-2002165207-A1
    优先权日:2001-05-02
    标题 :Compositions and methods for the treatment of diabetic neuropathy
    发明人:ROSENBLOOM RICHARD
    摘要:Compositions and a method for the treatment of diabetic neuropathy is disclosed. The compositions comprise a mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant, optionally formulated in a pharmaceutically acceptable carrier. This combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In addition, the compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. n In a second aspect, a method for the administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is administered on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms of diabetic neuropathy, as well as at least some recovery of the damaged nerve tissues.

    专利号:US-7914823-B2
    优先权日:2000-12-21
    标题 :Method and composition for the topical treatment of diabetic neuropathy
    发明人:ROSENBLOOM RICHARD ALLEN
    权利人:PROPHASE LABS INC
    摘要:A method and composition for the treatment of diabetic neuropathy is disclosed. The composition comprises a cold compounded mixture of a compound that promotes synthesis of nerve growth factor, an aldose reductase inhibitor and an antioxidant formulated in a pharmaceutically acceptable carrier. It has been found that this combination of active agents provides significant, effective relief of the symptoms of diabetic neuropathy, as well as at least partial recovery of lost neurological function in some cases. In view of the consensus in the art that effective combinations of various active agents have not been demonstrated to be effective for the treatment of diabetic neuropathy, the present invention provides a surprising and unexpected effect. In addition, the topical compositions of the present invention, when used in effective amounts to treat diabetic neuropathy, do not exhibit the severe side effects of many prior art compositions proposed for treatment of this ailment. n In a second aspect, a method for the topical administration of a composition in accordance with the present invention for the treatment of diabetic neuropathy is disclosed. In the method, an effective amount of the composition of the invention is topically administered to the areas of the body that have been adversely affected by the diabetic neuropathy on a regular basis over a period of time sufficient to provide the beneficial effects of relief from the symptoms and at least some recovery of the damaged nerve tissues.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Hou GR, Zeng K, Lan HM, Wang Q. Juglanin ameliorates UVB induced skin carcinogenesis via anti inflammatory and proapoptotic effects in vivo and in vitro. Int J Mol Med. 2018 Jul;42(1):41-52. doi: 10.3892/ijmm.2018.3601. Epub 2018 Mar 29. doi: 10.3892/ijmm.2018.3554. Epub 2018 Mar 9.
    3: Makule E, Schmidt TJ, Heilmann J, Kraus B. Diarylheptanoid Glycosides of Morella salicifolia Bark. Molecules. 2017 Dec 19;22(12). pii: E2266. doi: 10.3390/molecules22122266. doi: 10.18632/oncotarget.21317. eCollection 2017 Nov 7.
    5: Zhang FX, Xu RS. Juglanin ameliorates LPS-induced neuroinflammation in animal models of Parkinson's disease and cell culture via inactivating TLR4/NF-κB pathway. Biomed Pharmacother. 2018 Jan;97:1011-1019. doi: 10.1016/j.biopha.2017.08.132. Epub 2017 Nov 8. doi: 10.1016/j.bbrc.2017.09.132. Epub 2017 Sep 25. pii: E1100. doi: 10.3390/molecules22071100. doi: 10.1080/10286020.2017.1295228. Epub 2017 Mar 17. doi: 10.1016/j.biopha.2016.11.030. Epub 2016 Nov 26. doi: 10.1016/j.biopha.2016.04.013. Epub 2016 Apr 23. doi: 10.1016/j.jphotobiol.2015.10.016. Epub 2015 Oct 23. doi: 10.1007/s11418-014-0817-0. Epub 2014 Feb 12. doi: 10.1055/s-0033-1360277. Epub 2014 Jan 23. doi: 10.1007/s12272-013-0307-z. Epub 2013 Nov 29. doi: 10.1016/j.jpba.2013.10.037. Epub 2013 Nov 7. doi: 10.1016/j.fitote.2013.10.007. Epub 2013 Oct 19. doi: 10.1021/np300212c. Epub 2012 Oct 15. Chinese. doi: 10.1007/s12272-011-0404-9. Epub 2011 May 5. doi: 10.1055/s-0030-1250609. Epub 2010 Dec 14.

    合成参考文献


    参考文献:10.2147/dddt.s250904
    摘要:Liu J, Chen L, Zhang X, Pan L, Jiang L. The Protective Effects of Juglanin in Cerebral Ischemia Reduce Blood-Brain Barrier Permeability via Inhibition of VEGF/VEGFR2 Signaling. Drug Des Devel Ther. 2020;14():3165–75.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知